PT84880B - Processo para a preparacao de composicoes com accao fibrinolitica melhorada contendo um agente tensioactivo copolimerico - Google Patents

Processo para a preparacao de composicoes com accao fibrinolitica melhorada contendo um agente tensioactivo copolimerico Download PDF

Info

Publication number: PT84880B
Authority: PT; Portugal
Prior art keywords: approximately; integer; copolymer; groups; surfactant
Prior art date: 1986-05-15

Application number

PT84880A

Other languages

English (en)

Portuguese (pt)

Other versions

PT84880A (en

Inventor

Robert L Hunter

Alexander Duncan

Original Assignee

Univ Emory

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-05-15

Filing date

1987-05-15

Publication date

1990-02-08

1987-05-07 Priority claimed from US07/045,459 external-priority patent/US4801452A/en

1987-05-15 Application filed by Univ Emory filed Critical Univ Emory

1987-06-01 Publication of PT84880A publication Critical patent/PT84880A/pt

1990-02-08 Publication of PT84880B publication Critical patent/PT84880B/pt

Links

239000000203 mixture Substances 0.000 title claims abstract description 83
230000003480 fibrinolytic effect Effects 0.000 title claims abstract description 48
230000001976 improved effect Effects 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title claims description 59
239000002253 acid Substances 0.000 title 1
239000013543 active substance Substances 0.000 title 1
229920001577 copolymer Polymers 0.000 claims abstract description 107
208000007536 Thrombosis Diseases 0.000 claims abstract description 48
239000003527 fibrinolytic agent Substances 0.000 claims abstract description 47
150000001875 compounds Chemical class 0.000 claims abstract description 31
230000017531 blood circulation Effects 0.000 claims abstract description 26
101710196208 Fibrinolytic enzyme Proteins 0.000 claims abstract description 24
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 23
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 23
108010023197 Streptokinase Proteins 0.000 claims abstract description 19
229960005202 streptokinase Drugs 0.000 claims abstract description 19
229960005356 urokinase Drugs 0.000 claims abstract description 19
210000004204 blood vessel Anatomy 0.000 claims abstract description 18
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims abstract description 6
210000004369 blood Anatomy 0.000 claims description 48
239000008280 blood Substances 0.000 claims description 48
239000004094 surface-active agent Substances 0.000 claims description 47
230000008569 process Effects 0.000 claims description 40
102000009123 Fibrin Human genes 0.000 claims description 35
108010073385 Fibrin Proteins 0.000 claims description 35
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 35
229950003499 fibrin Drugs 0.000 claims description 35
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
206010028980 Neoplasm Diseases 0.000 claims description 32
230000002209 hydrophobic effect Effects 0.000 claims description 29
230000009089 cytolysis Effects 0.000 claims description 19
238000002360 preparation method Methods 0.000 claims description 19
239000011780 sodium chloride Substances 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 15
229910052760 oxygen Inorganic materials 0.000 claims description 13
239000001301 oxygen Substances 0.000 claims description 13
102000019197 Superoxide Dismutase Human genes 0.000 claims description 12
108010012715 Superoxide dismutase Proteins 0.000 claims description 12
239000003146 anticoagulant agent Substances 0.000 claims description 11
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
229930195725 Mannitol Natural products 0.000 claims description 7
235000010355 mannitol Nutrition 0.000 claims description 7
239000000594 mannitol Substances 0.000 claims description 7
208000007502 anemia Diseases 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
238000004090 dissolution Methods 0.000 claims description 5
230000010412 perfusion Effects 0.000 claims description 5
239000002516 radical scavenger Substances 0.000 claims description 5
108010073863 saruplase Proteins 0.000 claims description 5
210000000056 organ Anatomy 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 4
206010003210 Arteriosclerosis Diseases 0.000 claims description 3
208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
239000003153 chemical reaction reagent Substances 0.000 claims description 3
210000003743 erythrocyte Anatomy 0.000 claims description 3
229920000642 polymer Polymers 0.000 claims description 3
239000002904 solvent Substances 0.000 claims 5
229940127090 anticoagulant agent Drugs 0.000 claims 4
102000019400 Tissue-type plasminogen activator Human genes 0.000 claims 3
239000002246 antineoplastic agent Substances 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
208000007056 sickle cell anemia Diseases 0.000 claims 1
102000004190 Enzymes Human genes 0.000 abstract description 41
108090000790 Enzymes Proteins 0.000 abstract description 41
229940088598 enzyme Drugs 0.000 abstract description 41
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract description 5
102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract description 3
239000007859 condensation product Substances 0.000 abstract description 3
229960000187 tissue plasminogen activator Drugs 0.000 abstract description 3
125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 abstract description 2
239000000243 solution Substances 0.000 description 63
210000001519 tissue Anatomy 0.000 description 27
210000002216 heart Anatomy 0.000 description 18
230000000694 effects Effects 0.000 description 15
230000006378 damage Effects 0.000 description 13
210000001367 artery Anatomy 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 12
210000004351 coronary vessel Anatomy 0.000 description 12
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 11
208000028867 ischemia Diseases 0.000 description 11
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 10
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 10
230000004087 circulation Effects 0.000 description 10
238000001802 infusion Methods 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
208000032843 Hemorrhage Diseases 0.000 description 8
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
229920000669 heparin Polymers 0.000 description 8
229960002897 heparin Drugs 0.000 description 8
230000000302 ischemic effect Effects 0.000 description 8
238000011084 recovery Methods 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
102000001938 Plasminogen Activators Human genes 0.000 description 7
108010001014 Plasminogen Activators Proteins 0.000 description 7
239000011324 bead Substances 0.000 description 7
208000010125 myocardial infarction Diseases 0.000 description 7
229940127126 plasminogen activator Drugs 0.000 description 7
229920005862 polyol Polymers 0.000 description 7
150000003077 polyols Chemical class 0.000 description 7
102000008946 Fibrinogen Human genes 0.000 description 6
108010049003 Fibrinogen Proteins 0.000 description 6
238000002399 angioplasty Methods 0.000 description 6
208000034158 bleeding Diseases 0.000 description 6
230000000740 bleeding effect Effects 0.000 description 6
229940012952 fibrinogen Drugs 0.000 description 6
210000000440 neutrophil Anatomy 0.000 description 6
230000010410 reperfusion Effects 0.000 description 6
102000013566 Plasminogen Human genes 0.000 description 5
108010051456 Plasminogen Proteins 0.000 description 5
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 5
230000003213 activating effect Effects 0.000 description 5
229940127219 anticoagulant drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
230000002107 myocardial effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
238000007792 addition Methods 0.000 description 4
230000001010 compromised effect Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000009826 distribution Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000020764 fibrinolysis Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
210000004165 myocardium Anatomy 0.000 description 4
230000002195 synergetic effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
230000002885 thrombogenetic effect Effects 0.000 description 4
230000002861 ventricular Effects 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
238000012270 DNA recombination Methods 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
208000010378 Pulmonary Embolism Diseases 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000008021 deposition Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
210000005003 heart tissue Anatomy 0.000 description 3
239000012456 homogeneous solution Substances 0.000 description 3
230000007574 infarction Effects 0.000 description 3
230000004941 influx Effects 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000001338 necrotic effect Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
-1 superoxide ions Chemical class 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000002792 vascular Effects 0.000 description 3
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
206010011091 Coronary artery thrombosis Diseases 0.000 description 2
229940123457 Free radical scavenger Drugs 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
206010054094 Tumour necrosis Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000002583 angiography Methods 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
239000001045 blue dye Substances 0.000 description 2
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004413 cardiac myocyte Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000008602 contraction Effects 0.000 description 2
208000002528 coronary thrombosis Diseases 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229960003699 evans blue Drugs 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000002695 general anesthesia Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
238000006213 oxygenation reaction Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010009192 Circulatory collapse Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010069729 Collateral circulation Diseases 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
101100366942 Mus musculus Ston1 gene Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000001557 animal structure Anatomy 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
229940030602 cardiac therapy drug Drugs 0.000 description 1
239000000496 cardiotonic agent Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
230000010102 embolization Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
230000007760 free radical scavenging Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
230000000544 hyperemic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
201000003144 pneumothorax Diseases 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000018338 positive regulation of fibrinolysis Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000010453 quartz Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000009528 severe injury Effects 0.000 description 1
206010040560 shock Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT84880A 1986-05-15 1987-05-15 Processo para a preparacao de composicoes com accao fibrinolitica melhorada contendo um agente tensioactivo copolimerico PT84880B (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86358286A	1986-05-15	1986-05-15
US07/045,459 US4801452A (en)	1986-05-15	1987-05-07	Fibrinolytic composition

Publications (2)

Publication Number	Publication Date
PT84880A PT84880A (en)	1987-06-01
PT84880B true PT84880B (pt)	1990-02-08

Family

ID=26722792

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT84880A PT84880B (pt)	1986-05-15	1987-05-15	Processo para a preparacao de composicoes com accao fibrinolitica melhorada contendo um agente tensioactivo copolimerico

Country Status (6)

Country	Link
CA (1)	CA1297792C (fr)
GR (1)	GR870758B (fr)
IE (4)	IE922400L (fr)
NZ (1)	NZ220288A (fr)
PH (1)	PH25909A (fr)
PT (1)	PT84880B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2678873C (fr)	2007-02-19	2016-10-25	Plurogen Therapeutics, Inc.	Compositions pour traiter des biofilms, et procedes pour leur utilisation
WO2016118644A1 (fr)	2015-01-20	2016-07-28	Plurogen Therapeutics, Llc	Compositions et méthodes de traitement des microbes

1987
- 1987-05-13 NZ NZ220288A patent/NZ220288A/xx unknown
- 1987-05-13 CA CA000537052A patent/CA1297792C/fr not_active Expired - Lifetime
- 1987-05-14 IE IE922400A patent/IE922400L/xx not_active Application Discontinuation
- 1987-05-14 IE IE922401A patent/IE922401L/xx not_active Application Discontinuation
- 1987-05-14 IE IE922399A patent/IE922399L/xx not_active Application Discontinuation
- 1987-05-14 IE IE126187A patent/IE62088B1/en not_active IP Right Cessation
- 1987-05-15 GR GR870758A patent/GR870758B/el unknown
- 1987-05-15 PH PH35259A patent/PH25909A/en unknown
- 1987-05-15 PT PT84880A patent/PT84880B/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA1297792C (fr)	1992-03-24
IE922399L (en)	1987-11-15
IE871261L (en)	1987-11-15
IE62088B1 (en)	1994-12-14
IE922400L (en)	1987-11-15
NZ220288A (en)	1989-08-29
IE922401L (en)	1987-11-15
PT84880A (en)	1987-06-01
PH25909A (en)	1991-12-19
GR870758B (en)	1988-05-24

Legal Events

Date

Code

Title

Description

1998-05-29

MM3A

Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19980131

Publication	Publication Date	Title
US5089260A (en)	1992-02-18	Method of treating ischemic tissue
US4801452A (en)	1989-01-31	Fibrinolytic composition
US5017370A (en)	1991-05-21	Improved method of performing angioplasty procedures
EP0266419B1 (fr)	1994-03-02	Composition fibrinolytique
US5047236A (en)	1991-09-10	Method of treating stroke
US5028599A (en)	1991-07-02	Method of treating mycardial damage
US5078995A (en)	1992-01-07	Fibrionolytic composition
US5064643A (en)	1991-11-12	Method for treating sickle cell disease
US5080894A (en)	1992-01-14	Method and composition for reducing tissue damage
US4837014A (en)	1989-06-06	An improved method of treating sickle cell anemia
US4879109A (en)	1989-11-07	Method for treating burns
US4873083A (en)	1989-10-10	Fibrinolytic composition
US5039520A (en)	1991-08-13	Plasma extender
US5041288A (en)	1991-08-20	Method of treating tissue damaged by reperfusion injury
US4937070A (en)	1990-06-26	Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5032394A (en)	1991-07-16	Method of treating burns
US5250294A (en)	1993-10-05	Improved perfusion medium for transplantation of organs
US5648071A (en)	1997-07-15	Method of treating tumors
US5198211A (en)	1993-03-30	Method of treating myocardial damage
Seelig et al.	1996	Is there a place for magnesium in the treatment of acute myocardial infarction?
US5240702A (en)	1993-08-31	Method of treating stroke
US5240701A (en)	1993-08-31	Method of performing angioplasty procedures
EP0502554A2 (fr)	1992-09-09	Composition contenant un épurateur de radicause d'oxygène et un copolymère tensioactif
CA1297792C (fr)	1992-03-24	Composition fibrinolytique
WO1995012310A1 (fr)	1995-05-11	Composition permettant d'assurer la conservation des organes et tissus a transplanter